Pantherna Therapeutics is a biopharmaceutical company developing therapeutics for vascular diseases using a technology platform of advanced nanoparticles to deliver and express therapeutic mRNA drugs, including candidates aimed at treating Acute Respiratory Distress Syndrome (ARDS). The platform is described as unfolding into further applications beyond ARDS. The company is led by Dr. Klaus Giese (CEO), Jörg Kaufmann (CSO), Gerrit Maass (CFO) and Oliver Keil (CTO). Pantherna is based in Hennigsdorf, Germany. It secured seed financing to advance its R&D activities and to hire additional scientific staff. The financing position improves the company’s ability to progress preclinical development of its mRNA delivery platform.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2019